Dramatic response to osimertinib combined with crizotinib in EGFR T790 M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer: A case report

RATIONALE: Besides the T790 M mutation, it may coexist with bypass pathway activation in real clinical cases for patients with EGFR mutations who resisted to the first- and second-generation tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). There are limited clinical trial dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dapeng, Gui, Qi, Xu, Caihua, Shen, Meng, Chen, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322536/
https://www.ncbi.nlm.nih.gov/pubmed/34397683
http://dx.doi.org/10.1097/MD.0000000000026375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322536/
https://www.ncbi.nlm.nih.gov/pubmed/34397683
http://dx.doi.org/10.1097/MD.0000000000026375

Ejemplares similares